Q-omics provides the consensus-scored KCTD2 profile across patient tissues and cancer cell-line models. KCTD2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCTD2 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, KCTD2 RNA expression shows 19,970 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where KCTD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD2 survival associations across molecular data types. KCTD2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD2 RNA expression–survival associations across cancer types. High KCTD2 expression shows unfavorable associations in KICH, LIHC, LUSC and ACC, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCTD2 RNA expression.
This table summarizes KCTD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KCTD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD2 shows lower tumor expression in THCA, KICH and COAD and higher tumor expression in LIHC, KIRP and CHOL. The THCA box plot shows higher KCTD2 RNA expression in normal versus tumor tissue (log2 FC = −1.228, t-test p < 0.001).
This table shows molecular features associated with KCTD2 in patient tissues and cancer cell lines. In patient samples, KCTD2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCTD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
